UPDATE: Catalyst Bio FDA AccessData.gov Listing Dated Dec. 15, 2021
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=820721
Catalyst Bio FDA AccessData.gov Listing Shows Orphan Drug Designation For Co.’s ‘ Treatment of Bleeding Episodes in Patients with Hemophilia A or B, Including those with Inhibitors’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=820721
70 Biggest Movers From Friday
Gainers
Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
What Is Happening With Catalyst Biosciences Shares Today?
Catalyst Biosciences Inc (NASDAQ:CBIO) has decided to halt the clinical development of MarzAA (engineered FVIIa) and focus solely on complement programs…
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours:
Catalyst Biosciences Sponsored Study Titled ‘Screening Study to Identify Patients With Complement Factor I Deficiencies’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05072912
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
Catalyst Biosciences’ Lead Candidate Secures Orphan Drug Tag For Blood Clotting Disorder
The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc’s (NASDAQ:CBIO) Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency…